Lnc524369 promotes hepatocellular carcinoma progression and predicts poor survival by activating YWHAZ-RAF1 signaling

BACKGROUND Liver cancer is one of the most highly malignant cancers,characterized by easy metastasis and chemoradiotherapy resistance.Emerging evidence indicates that long noncoding RNAs(LncRNAs),including Lnc524369,are highly involved in the initiation,progression,radioresistance,and chemoresistance of hepatocellular carcinoma(HCC).However,the function of Lnc524369 remains unclear.AIM To explore the function of Lnc524369 in HCC.METHODS To investigate the effect of Lnc524369,tissue from 41 HCC patients were analyzed using CCK8,migration,and invasion assays.Lnc524369 and YWHAZ(also named 14-3-3ζ)mRNA were detected by qPCR,and YWHAZ and RAF1 proteins were detected by western blot in liver cancer cell lines and human HCC tissues.The Cancer Cell Line Encyclopedia(CCLE)databases,STRING database,Human Protein Atlas database,and the TCGA database were used for bioinformatic analysis.RESULTS Lnc524369 was significantly upregulated in the nucleus of liver cancer cells and human HCC tissues.Overexpression of Lnc524369 was associated with the proliferation,migration,and invasion of liver cancer cells.YWHAZ and RAF1 proteins and YWHAZ mRNA were overexpressed in liver cancer,which could be attenuated by overexpression of Lnc524369.Lnc524369 and its downstream target YWHAZ and RAF1 proteins were negatively associated with overall survival time.CONCLUSION Lnc524369 might be a promising target of HCC as it can enhance liver cancer progression and decrease the overall survival time of HCC by activating the YWHAZ/RAF1 pathway.

Transcatheter arterial chemoembolization after percutaneous microwave ablation and portal vein embolization for advanced hepatocellular carcinoma

To the Editor: Associating liver partition and portal vein ligation for staged hepatectomy(ALPPS) promotes the future liver remnant(FLR) rapid proliferation in the short term, which in turn provides an opportunity for radical surgical resection to hepatocellular carcinoma(HCC) for patients with insufficient FLR [ 1, 2 ].

Cynaroside regulates the AMPK/SIRT3/Nrf2 pathway to inhibit doxorubicin-induced cardiomyocyte pyroptosis

Doxorubicin(DOX)is a commonly administered chemotherapy drug for treating hematological malignancies and solid tumors;however,its clinical application is limited by significant cardiotoxicity.Cynaroside(Cyn)is a flavonoid glycoside distributed in honeysuckle,with confirmed potential biological functions in regulating inflammation,pyroptosis,and oxidative stress.Herein,the effects of Cyn were evaluated in a DOX-induced cardiotoxicity(DIC)mouse model,which was established by intraperitoneal injections of DOX(5 mg/kg)once a week for three weeks.The mice in the treatment group received dexrazoxane,MCC950,and Cyn every two days.Blood biochemistry,histopathology,immunohistochemistry,reverse transcription-quantitative polymerase chain reaction(RT-qPCR),and western blotting were conducted to investigate the cardioprotective effects and potential mechanisms of Cyn treatment.The results demonstrated the significant benefits of Cyn treatment in mitigating DIC;it could effectively alleviate oxidative stress to a certain extent,maintain the equilibrium of cell apoptosis,and enhance the cardiac function of mice.These effects were realized via regulating the transcription levels of pyroptosis-related genes,such as nucleotide-binding oligomerization domain-like receptor protein 3(NLRP3),caspase-1,and gasdermin D(GSDMD).Mechanistically,for DOX-induced myocardial injury,Cyn could significantly modulate the expression of pivotal genes,including adenosine monophosphate-activated protein kinase(AMPK),peroxisome proliferator-activated receptorγcoactivator-1α(PGC-1α),sirtuin 3(SIRT3),and nuclear factor erythroid 2-related factor 2(Nrf2).We attribute it to the mediation of AMPK/SIRT3/Nrf2 pathway,which plays a central role in preventing DOX-induced cardiomyocyte injury.In conclusion,the present study confirms the therapeutic potential of Cyn in DIC by regulating the AMPK/SIRT3/Nrf2 pathway.